全球首发！三优超万亿创新抗体药发现平台震撼发布！

　　当地时间2022年6月3日，三优生物医药（上海）有限公司正式发布了其具有自主产权的三优超万亿创新抗体药发现平台（STAL）。

　　三优超万亿创新抗体药发现平台是由三优生物历时7年持续创新、自主研发而成，是在三优生物超千亿创新抗体发现平台的基础上取得的重大突破。超万亿创新抗体药发现平台集成了九种类型的超万亿创新抗体库，设计库容高达十万亿；数十个靶点的筛选验证表明，利用超万亿创新抗体药发现平台，针对常见靶点可筛选获得数千个创新型先导分子，先导分子数量是传统方法的数十乃至数百倍。

　　众所周知，全球每年有数亿患者受到癌症、自免、过敏和代谢疾病的困扰。单抗药物、双抗药物、ADC药物、AOC药物、抗体与核素偶联药物、PDC药物和CAR-T免疫细胞疗法等是治疗这些重大疾病的主流方法；该类药物已有100多种获批上市，已累积造福了数亿患者，年销售额高达近2000亿美元；特异性的抗体分子是这些药物共有的核心元件，发挥着精准靶向的重要作用。

　　三优超万亿创新抗体药发现平台无缝衔接了“噬菌体展示”与“哺乳动物细胞蛋白表达”分子产生技术，搭载了全自动化筛选和一体化抗体药物研发平台，适合挑战高难创新靶点，也适用于开发高难新型分子；多样化的抗体库可匹配“全人抗体、人源化单域抗体、人源化单抗、双抗、多抗、多肽、ADC、PDC、小型化蛋白”等多种创新大分子药物的研发需求，所获分子具有“接近天然、亲和力高、可开发性优异”的特点。

　　三优超万亿创新抗体药发现平台配备了以客户需求为中心，模块化、多样化和定制化的业务体系，不仅适用于各类创新大分子药物的研发，还适用于疾病机制研究、诊断产品等的研发。目前，利用三优生物的创新抗体药发现平台研发的药物已有数十个项目完成了临床前候选分子筛选，多个项目完成了临床前研发并已推进到临床研发阶段。

　　三优生物CEO

　　三优生物CEO郎国竣博士表示：

　　创新药物的研发已经逐步步入到了挑战高难创新靶点、开发高难创新分子、攻关高难度复杂疾病的‘三难创新’时代。

　　三优超万亿创新抗体药发现平台含有九大超万亿抗体库，所获先导分子数量是传统抗体制备技术的数十到数百倍；该平台集成了全人抗体、人源化抗体、小型化纳米抗体、靶向多肽分子和靶向新型蛋白分子等多样化的大分子药物产生技术，不仅适用于开发靶向常规表位的抗体，也适用于开发靶向特殊表位、精细化表位的抗体；该平台将噬菌体展示技术和哺乳动物细胞表达技术进行了无缝隙整合，既适合针对人、鼠、猴蛋白等不同物种蛋白的交叉筛选，又适合针对突变位点、竞争分子、Fc融合蛋白、His融合蛋白等差异化蛋白的正负筛选，还适合针对细胞抗原、多肽抗原、膜蛋白抗原等高难度靶点的复杂筛选。

　　三优超万亿创新抗体药发现平台与三优生物的创新抗体药物临床前一体化平台进行了模块化的整合，既可灵活的开展各类抗体发现服务、特色技术服务和阶段技术服务，又可一站式的完成临床前候选药物分子发现和临床前抗体大分子药物一体化研发；在该平台的基础上，三优生物还在并行开展智能化创新抗体药物发现平台建设。

　　相信，三优生物的‘创新抗体药物临床前一体化平台、超万亿创新抗体药发现平台、智能化创新抗体药物发现平台’‘三驾马车’并行驱动，将极大的助力广大合作伙伴突破内卷，从容应对‘三难创新’，开发出更加优质的创新药物，造福广大病患。

　　关于三优生物

　　三优生物是一家专注于创新抗体药物研发和服务的生物高科技企业。公司致力于打造国际领先的创新抗体药高质量、高通量、集成化研发及价值转化平台，构建治疗、研发和诊断类产品与服务的业务生态系统，协同全球生物制药、诊断及药物研发公司，打开人类疾病诊断和治疗的新局面。

　　三优生物建立了20000余平方米、设施设备先进齐全的创新抗体药物一体化研发实验室。打造了以系列万亿级噬菌体展示抗体库为代表的，涵盖创新抗体药发现、创新抗体药优化、生产用细胞株构建、上下游工艺开发、临床前研发及产业化开发等的40多个核心创新技术平台。构建了“差异化CRO、创新型CPO、特色CRS”于一体的业务体系。公司持续推出“品质最好、速度最快、性价比最高”（三优）的新技术、新产品、新服务和新场景。公司已和全球300多家制药公司、药物研发机构、诊断试剂产品公司建立了友好的业务合作关系。

　　World Premiere | Sanyou Super-Trillion Innovative Antibody Drug Discovery Platform Announced!

　　Sanyou Biopharmaceuticals officially launched STAL (Super-Trillion Antibody Libraries) on June 3, 2022, which is a super-trillion innovative antibody drug discovery platform of Sanyou’s own intellectual property.

　　Developed by Sanyou after seven years of continuous innovation and independent R&D, STAL represents a significant breakthrough over the previous generation of the sub-trillion innovative antibody discovery platforms. The STAL discovery platform integrates nine categories of super-trillion innovative antibody libraries with the overall library capacity up to 10 trillion. The screening validations with dozens of targets showed that thousands of innovative lead antibodies can be discovered via the STAL platform, and the quantity is dozens or even hundreds of times that of canonical methods.

　　Hundreds of millions of patients worldwide are suffering from cancer, autoimmune diseases, allergic diseases and metabolic diseases every year. Drugs including monoclonal antibody, bispecific antibody, ADC, AOC, RAC, PDC and CAR-T therapy are the mainstream treatments for these diseases. More than 100 of biological drugs have been approved with total annual market revenue approaching $200 billion. Antibodies with high specificities are the common core components of these drugs and play an important role in precise targeting.

　　The STAL discovery platform integrates technologies of phage display and mammalian cell expression, and is supplemented with fully automated screening and integrated antibody drug R&D platforms. The STAL is effective for challenging innovative targets and development of highly difficult drug modalities. It can meet the R&D needs related to the discovery of various innovative biological drugs, including fully human antibodies, humanized single domain antibodies, humanized monoclonal antibodies, bispecific antibodies, multi-specific antibodies, polypeptides, ADC, PDC and miniaturized proteins. The obtained candidates have natural conformations, high affinity and high developability.

　　The STAL discovery platform is underpinned by a client-oriented, modular, diversified, and customized business system, which is not only applicable to the R&D of various innovative biological drugs, but also to the research of disease mechanisms and development of the diagnostic products. Dozens of projects from the platform have delivered the pre-clinical candidates, several projects have completed the pre-clinical R&D and entered the clinical phase.

　　Dr. Guojun Lang, CEO of Sanyou said: "the research and development of innovative drugs has gradually entered a challenging era where we to overcome highly difficult innovative targets, novel drug modalities and intriguingly complex diseases ".

　　"The STAL Discovery Platform comprises nine super-trillion antibody libraries, with the number of lead antibodies up to hundreds of times that of canonical antibody discovery technologies. The platform integrates the generation technologies of a variety of biological drugs such as fully human antibodies, humanized antibodies, miniaturized nanobodies, affinitive polypeptides, and affinitive miniaturized proteins, so that it is suitable not only for developing antibodies targeting conventional epitopes, but also for developing antibodies targeting specific epitopes and refined epitopes. Also, the platform seamlessly integrates phage display technology and mammalian cell expression technology so that it is suitable not only for cross-screening with proteins of different species such as human, mouse, and monkey, but also for positive/negative screening of differentiated proteins such as mutation sites, competing antibodies, Fc fusion proteins and His fusion proteins, as well as for complex screening of difficult targets such as cellular antigens, polypeptide antigens, and transmembrane antigens."

　　"The STAL Discovery Platform has been modularly integrated with the Pre-Clinical Integrated Innovative Antibody Drug R&D Platform. As a result, various antibody discovery services, featured technical services and staged technical services can be implemented flexibly, and pre-clinical candidate discovery and integrated R&D of pre-clinical biological drugs can be completed as an one-stop solution. On the basis of this platform, Sanyou is also developing an intelligent innovative antibody drug discovery platform."

　　"It is believed that the Pre-Clinical Integrated Innovative Antibody Drug R&D Platform, the STAL Discovery Platform, and the Intelligent Innovative Antibody Drug Discovery Platform of Sanyou will prominently help our partners to lead the competition, overcome difficulties in drug innovations, and develop more high-quality innovative drugs to benefit the patients."

　　About Sanyou Biopharmaceuticals

　　Sanyou Biopharmaceuticals Co., Ltd. is a world-leading biotechnology and high-tech enterprise focusing on R&D and services of innovative antibody drugs.

　　Sanyou is committed to establishing an internationally leading high-quality, high-throughput and integrated R&D and value transformation platform for innovative antibody drugs, constructing a business ecosystem including therapy, R&D, and diagnostic products and services, and cooperating with global biopharmaceutical, diagnostic, and drug R&D companies to make a new progress in the diagnosis and treatment of human diseases.

　　Sanyou has established an integrated innovative antibody drug R&D laboratory of several thousand square meters with advanced facilities. There are 10 major functional modules and more than 40 core technological platforms, which are featured by a series of Super-Trillion phage display antibody libraries and integrated platforms covering innovative antibody drug discovery, innovative antibody drug optimization, production cell line construction, upstream and downstream process development, preclinical R&D and industrial development, etc.

　　Sanyou has built a business system that integrates "differentiated CRO, innovative CPO and characteristic CRS”, and consistently launches new technologies, new products, new services, and new scenarios base on the principle of high quality, fast delivery and cost-efficiency. Friendly business collaborations have been established with more than 300 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide.

　　举报/反馈